bioRxivImmunology
Live imaging of SARS-CoV-2 infection in mice reveals neutralizing antibodies require Fc function for optimal efficacy
I. Ullah, J. Prevost, M. S. Ladinsky, H. Stone, M. Lu, S. P. Anand, G. Beaudoin-Bussieres, K. Symmes, M. Benlarbi, S. Ding, R. Gasser, C. Fink, Y. Chen, A. Tauzin, G. Goyette, C. Bourassa, H. Medjahed, M. Mack, K. Chung, C. B. Wilen, G. A. Dekaban, J. D. Dikeakos, E. A. Bruce, D. E. Kaufmann, L. Stamatatos, , P. D. Uchil
Abstract
Neutralizing antibodies (NAbs) are effective in treating COVID-19 but the mechanism of immune protection is not fully understood. Here, we applied live bioluminescence imaging (BLI) to monitor the real-time effects of NAb treatment in prophylaxis and therapy of K18-hACE2 mice intranasally infected with SARS-CoV-2-nanoluciferase. We could visualize virus spread sequentially from the nasal cavity to the lungs and thereafter systemically to various organs including the brain, which culminated in death. Highly potent NAbs from a COVID-19 convalescent subject prevented, and also effectively resolved, established infection when administered within three days. In addition to direct Fab-mediated neutralization, Fc effector interactions of NAbs with monocytes, neutrophils and natural killer cells were required to effectively dampen inflammatory responses and limit immunopathology. Our study highlights that both Fab and Fc effector functions of NAbs are essential for optimal in vivo efficacy against SARS-CoV-2.
- organism: mouse
- assay: imaging
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions
C. N. Pierre, L. E. Adams, … K. Saunders·bioRxiv·Jul 25, 2023
- Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection
E. S. Winkler, P. Gilchuk, … M. Diamond·bioRxiv·Dec 28, 2020
- The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody
C. E. Z. Chan, S. G. K. Seah, … B. J. Hanson·bioRxiv·Oct 26, 2020
- Fc-independent neutralization of SARS-CoV-2 by recombinant human monoclonal antibodies
T. Noy-Porat, A. Edri, … O. Mazor·bioRxiv·May 15, 2021
- An anti-SARS-CoV-2 non-neutralizing antibody with Fc-effector function defines a new NTD epitope and delays neuroinvasion and death in K18-hACE2 mice
G. Beaudoin-Bussieres, Y. Chen, … A. Finzi·bioRxiv·Sep 8, 2021
- The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates
D. Li, R. J. Edwards, … Petzol·bioRxiv·Dec 31, 2020